Related by context. Frequent words. (Click for all words.) 86 Preclinical Data 85 Drug Candidate 85 Phase III Trial 84 Phase III Clinical Trial 84 Completes Enrollment 82 Patient Enrollment 82 Presents Positive 81 Pivotal Phase III 80 Metastatic Melanoma 80 Pivotal Trial 79 Patients Treated 79 Pivotal Phase 79 Low Dose 78 FDA Accepts 78 Monotherapy 78 Chronic Hepatitis C 77 Postmenopausal Women 77 Overactive Bladder 77 Meta Analysis 77 FDA Clears 77 Heart Failure Patients 77 Pulmonary Arterial Hypertension 76 Study Demonstrates 76 Elderly Patients 76 RNAi Therapeutics 76 Metastatic Colorectal Cancer 76 Initiates Phase 76 Receives FDA Clearance 76 Significantly Reduces 76 Combination Therapy 75 Monoclonal Antibody 75 Tolerability 75 Clinical Study 74 Small Molecule 74 Benign Prostatic Hyperplasia 74 Prostate Cancer Patients 74 Chronic Lymphocytic Leukemia 74 Generic Version 74 Cholesterol Drug 74 Advanced Prostate Cancer 73 Announces Initiation 73 Non Invasive 73 Cancer Treatments 73 Announces Publication 73 Diabetic Patients 73 Shows Promise 73 Announces Presentation 73 FDA Approves 73 Autoimmune Diseases 73 Prostate Cancer Treatment 72 Oral Presentation 72 Smallpox Vaccine 72 FDA Clearance 72 Atopic Dermatitis 72 Drug Resistant 72 Breast Cancer Patients 72 Solid Tumors 72 Malaria Vaccine 72 Immunogenicity 71 Inhibits 71 Cardiovascular Events 71 Study Indicates 71 Positive Opinion 71 Urinary Incontinence 71 Reduces Risk 71 Cancer Cells 71 Extended Release 71 Drug Eluting Stent 71 Bladder Cancer 71 Drug Eluting Stents 71 Insulin Resistance 71 Clinical Trial 71 Acute Myocardial Infarction 70 Cethromycin 70 Announces Positive 70 Poster Presentation 70 Dasatinib 70 Epratuzumab 70 Increases Risk 70 Breast Cancer Treatment 70 Increased Risk 70 Reports Positive 70 Hepatitis C Virus 70 Induces 70 Randomized Controlled Trial 70 Successful Completion 70 J Am Coll 70 Bortezomib 70 Positive Results 70 Monoclonal Antibodies 70 Multicenter 69 Enoxaparin 69 Receives Positive 69 Hormone Therapy 69 Pirfenidone 69 Targeted Therapy 69 Oritavancin 69 Peripheral Artery Disease 69 Study Confirms 69 Bavituximab 68 Pharmacokinetic